Home > Research projects >Projects in Pr-clinical Studies

Projects in Pr-clinical Studies

      When the Hemay Group Corporation was first established, it was determined that we engage in research and development on category 1 new drug entities. After more than 10 years hard work, we have established two R&D platforms: one for and one for anti-cancer drugs.

We are in the leading position in the R&D platform of Immunomodulatory drugs for both at home and aboard. In this platform, we have a dozens of projects of category 1 Immunomodulatory drugs and we have decided on the candidate compounds (Hemay001, Hemay808, Hemay818, Hemay805 and Hemay211). The indications of these projects are rheumatoid arthritis, inflammatory bowel disease, psoriasis, sepsis, atopic dermatitis, chronic obstructive pulmonary disease (COPD), all of which are immunological system disorders. Among them, Hemay805 can restrain the cytokine release syndrome caused by virus infection; and we are expecting that this drug would be applied in fields like influenza, SARS, swine influenza and avian influenza.

In the antitumor drug R&D platform, we have projects of low toxicity-irreversible small molecule tyrosine kinase inhibitor (Hemay020 and Hemay022), inhibitor of nicotinamide phosphoribosyttransferase (NAMPT) (Hemay088), PSA Antigen–Activated Peptide-drug Conjugate (Hemay107) and HER2-targeted antibody-drug conjugate drugs. The indications of these projects are kidney cancer, pancreatic cancer, triple negative breast cancer, colon cancer, hepatocellular carcinoma and gastric cancer.

All rights reserved (2017), tianjin ICP for 05010040